Recent developments in thrombin-activatable fibrinolysis inhibitor research

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 10, 2009, Pages 1165-1173

  Marx, Pauline F ^a   Verkleij, Chantal J N ^a   Seron, Mercedes Valls ^a   Meijers, Joost C M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Carboxypeptidase B; Carboxypeptidase R; Carboxypeptidase U; Fibrinolysis; Inflammation; TAFI

Indexed keywords

ANTIFIBRINOLYTIC AGENT; ARGININE CARBOXYPEPTIDASE; CARBOXYPEPTIDASE; ENZYME PRECURSOR; METALLOCARBOXYPEPTIDASE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR A; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR A INHIBITOR; UNCLASSIFIED DRUG;

AUTOREGULATION; BLOOD CLOTTING; CELL MIGRATION; CEREBROVASCULAR ACCIDENT; CRYSTAL STRUCTURE; FIBRINOLYSIS; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; INFLAMMATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; WOUND HEALING;

ANIMALS; CARBOXYPEPTIDASE U; GENE EXPRESSION; HUMANS; MODELS, MOLECULAR;

EID: 70450212621     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709789055216     Document Type: Review

References (122)

1. Gils, A. Which carboxypeptidase determines the antifibrinolytic potential? J. Thromb. Haemost., 2008, 6, 846-847
2. Boffa, M. B.; Koschinsky, M. L. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin. Biochem., 2007, 40, 431-442
3. Bouma, B. N.; Mosnier, L. O. Thrombin activatable fibrinolysis inhibitor (TAFI)-how does thrombin regulate fibrinolysis? Ann. Med., 2006, 38, 378-388 (Pubitemid 44484876)
4. Willemse, J. L.; Hendriks, D. F. A role for procarboxypepidase U (TAFI) in thrombosis. Front Biosci., 2007, 12, 1973-1987
5. Mosnier, L. O.; Bouma, B. N. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 2445-2453
6. Leurs, J.; Hendriks, D. Carboxypeptidase U (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease. Thromb. Haemost., 2005, 94, 471-487
7. Bouma, B. N.; Mosnier, L. O. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. Pathophysiol. Haemost. Thromb., 2003, 33, 375-381 (Pubitemid 40278711)
8. Marx, P. F. Thrombin-activatable fibrinolysis inhibitor. Curr. Med. Chem., 2004, 11, 2311-2324
9. Rijken, D. C.; Lijnen, H. R. New insights into the molecular mechanisms of the fibrinolytic system. J. Thromb. Haemost., 2008.
10. Leung, L. L.; Nishimura, T.; Myles, T. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Adv. Exp. Med. Biol., 2008, 632, 61-69
11. Binette, T. M.; Taylor, F. B., Jr.; Peer, G.; Bajzar, L. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon. Blood, 2007, 110, 3168-3175 (Pubitemid 350106308)
12. Bajzar, L.; Morser, J.; Nesheim, M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J. Biol. Chem., 1996, 271, 16603-16608
13. Eaton, D. L.; Malloy, B. E.; Tsai, S. P.; Henzel, W.; Drayna, D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J. Biol. Chem., 1991, 266, 21833-21838 (Pubitemid 121000257)
14. Mao, S. S.; Cooper, C. M.; Wood, T.; Shafer, J. A.; Gardell, S. J. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B - modulation by glycosaminoglycans. J. Biol. Chem., 1999, 274, 35046-35052
15. Marx, P. F.; Dawson, P. E.; Bouma, B. N.; Meijers, J. C. Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor. Biochemistry, 2002, 41, 6688-6696 (Pubitemid 34547359)
16. Kawamura, T.; Okada, N.; Okada, H. Elastase from activated human neutronpils activates procarboxypeptidase R. Microbiol. Immunol., 2002, 46, 225-230 (Pubitemid 34289020)
17. Marx, P. F.; Hackeng, T. M.; Dawson, P. E.; Griffin, J. H.; Meijers, J. C. M.; Bouma, B. N. Inactivation of activated thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage. J. Biol. Chem., 2000, 275, 12410-12415
18. Boffa, M. B.; Bell, R.; Stevens, W. K.; Nesheim, M. E. Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor. J. Biol. Chem., 2000, 275, 12868-12878
19. Marx, P. F.; Bouma, B. N.; Meijers, J. C. Role of zinc ions in activation and inactivation of thrombin-activatable fibrinolysis inhibitor. Biochemistry, 2002, 41, 1211-1216 (Pubitemid 34083773)
20. Marx, P. F.; Plug, T.; Havik, S. R.; Morgelin, M.; Meijers, J. C. The activation peptide of thrombin-activatable fibrinolysis inhibitor: a role in activity and stability of the enzyme? J. Thromb. Haemost., 2008,
21. Marx, P. F.; Havik, S. R.; Marquart, J. A.; Bouma, B. N.; Meijers, J. C. M. Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor. J. Biol. Chem., 2004, 279, 6620-6628
22. Marx, P. F.; Havik, S. R.; Bouma, B. N.; Meijers, J. C. M. Role of isoleucine residues 182 and 183 in thrombin-activatable fibrinolysis inhibitor. J. Thromb. Haemost., 2005, 3, 1293-1300
23. Knecht, W.; Willemse, J.; Stenhamre, H.; Andersson, M.; Berntsson, P.; Furebring, C.; Harrysson, A.; Hager, A. C.; Wissing, B. M.; Hendriks, D.; Cronet, P. Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demonstrates the importance of CPU stability over proCPU concentration in down-regulating fibrinolysis. FEBS J., 2006, 273, 778-792
24. Ceresa, E.; De Maeyer, M.; Jonckheer, A.; Peeters, M.; Engelborghs, Y.; Declerck, P. J.; Gils, A. Comparative evaluation of stable TAFIa variants: importance of alpha-helix 9 and beta-sheet 11 for TAFIa (in)stability. J. Thromb. Haemost., 2007, 5, 2105-2112 (Pubitemid 47450030)
25. Ceresa, E.; Peeters, M.; Declerck, P. J.; Gils, A. Announcing a TAFIa mutant with a 180-fold increased half-life and concomitantly a strongly increased antifibrinolytic potential. J. Thromb. Haemost., 2007, 5, 418-420 (Pubitemid 46139471)
26. Ceresa, E.; Van de Borne, K.; Peeters, M.; Lijnen, H. R.; Declerck, P. J.; Gils, A. Generation of a stable activated thrombin activable fibrinolysis inhibitor variant. J. Biol. Chem., 2006, 281, 15878-15883 (Pubitemid 43848479)
27. Marx, P. F.; Brondijk, T. H.; Plug, T.; Romijn, R. A.; Hemrika, W.; Meijers, J. C.; Huizinga, E. G. Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI; A novel mechanism for enzyme auto-regulation. Blood, 2008, 112, 2803-2809
28. Sanglas, L.; Valnickova, Z.; Arolas, J. L.; Pallares, I.; Guevara, T.; Sola, M.; Kristensen, T.; Enghild, J. J.; Aviles, F. X.; Gomis-Ruth, F. X. Structure of activated thrombin-activatable fibrinolysis inhibitor, a molecular link between coagulation and fibrinolysis. Mol. Cell, 2008, 31, 598-606.
29. Anand, K.; Pallares, I.; Valnickova, Z.; Christensen, T.; Vendrell, J.; Wendt, K. U.; Schreuder, H. A.; Enghild, J. J.; Aviles, F. X. The crystal structure of TAFI provides the structural basis for its intrinsic activity and the short half-life of TAFIa. J. Biol. Chem., 2008, 283, 29416-29423
30. Barbosa Pereira, P. J.; Segura-Martin, S.; Oliva, B.; Ferrer-Orta, C.; Aviles, F. X.; Coll, M.; Gomis-Ruth, F. X.; Vendrell, J. Human procarboxypeptidase B: three-dimensional structure and implications for thrombin-activatable fibrinolysis inhibitor (TAFI). J. Mol. Biol., 2002, 321, 537-547
31. Coll, M.; Guasch, A.; Avilés, F. X.; Huber, R. Three-dimensional structure of pocine procarboxypeptidase B: a structural basis of its inactivity. EMBO J., 1991, 10, 1-9. (Pubitemid 21905260)
32. Guasch, A.; Coll, M.; Aviles, F. X.; Huber, R. Three-dimensional structure of procine pancreatic procarboxypeptidase A. A comparison of the A and B zymogens and their determinants for inhibition and activation. J. Mol. Biol., 1992, 224, 141-157
33. Garcia-Saez, I.; Reverter, D.; Vendrell, J.; Aviles, F. X.; Coll, M. The three-dimensional structure of human procarboxypeptidase A2. Deciphering the basis of the inhibition, activation and intrinsic activity of the zymogen. EMBO J., 1997, 16, 6906-6913 (Pubitemid 27520791)
34. Gomis-Ruth, F. X.; Gomez, M.; Bode, W.; Huber, R.; Aviles, F. X. The three-dimensional structure of the native ternary complex of bovine pancreatic procarboxypeptidase A with proproteinase E and chymotrypsinogen C. EMBO J., 1995, 14, 4387-4394
35. Valnickova, Z.; Christensen, T.; Skottrup, P.; Thogersen, I. B.; Hojrup, P.; Enghild, J. J. Post-translational modifications of human thrombin-activatable fibrinolysis inhibitor (TAFI): evidence for a large shift in the isoelectric point and reduced solubility upon activation. Biochemistry, 2006, 45, 1525-1535
36. Buelens, K.; Hillmayer, K.; Compernolle, G.; Declerck, P. J.; Gils, A. Biochemical importance of glycosylation in thrombin activatable fibrinolysis inhibitor. Circ. Res., 2008, 102, 295-301. (Pubitemid 351271649)
37. Valnickova, Z.; Thogersen, I. B.; Potempa, J.; Enghild, J. J. Thrombin-activable fibrinolysis inhibitor (TAFI) zymogen is an active carboxypeptidase. J. Biol. Chem., 2007, 282, 3066-3076
38. willemse, J. L.; Polla, M.; Hendriks, D. F. The intrinsic enzymatic activity of plasma procarboxypeptidase U (TAFI) can interfere with plasma carboxypeptidase N assays. Anal. Biochem., 2006, 356, 157-159
39. Foley, J. H.; Kim, P.; Nesheim, M. E. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis. J. Biol. Chem., 2008, 283, 8863-8867
40. Willemse, J. L.; Heylen, E.; Hendriks, D. F. The intrinsic enzymatic activity of procarboxypeptidase U (TAFI) does not significantly influence the fibrinolysis rate: a rebuttal. J. Thromb. Haemost., 2007, 5, 1334-1336 (Pubitemid 46902143)
41. Walker, J. B.; Binette, T. M.; Mackova, M.; Lambkin, G. R.; Mitchell, L.; Bajzar, L. Proteolytic cleavage of carboxypeptidase N markedly increases its antifibrinolytic activity. J. Thromb. Haemost., 2008, 6, 848-855
42. Adler, M.; Buckman, B.; Bryant, J.; Chang, Z.; Chu, K.; Emayan, K.; Hrvatin, P.; Islam, I.; Morser, J.; Sukovich, D.; West, C.; Yuan, S.; Whitlow, M. Structures of potent selective peptide mimetics bound to carboxypeptidase B. Acta Crystallogr. D. Biol. Crystallogr., 2008, 64, 149-157 (Pubitemid 351161590)
43. Adler, M.; Bryant, J.; Buckman, B.; Islam, I.; Larsen, B.; Finster, S.; Kent, L.; May, K.; Mohan, R.; Yuan, S.; Whitlow, M. Crystal structures of potent thiol-based inhibitors bound to carboxypeptidase B. Biochemistry, 2005, 44, 9339-9347 (Pubitemid 40934384)
44. Islam, I.; Bryant, J.; May, K.; Mohan, R.; Yuan, S.; Kent, L.; Morser, J.; Zhao, L.; Vergona, R.; White, K.; Adler, M.; Whitlow, M.; Buckman, B. O. 3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorg. Med. Chem. Lett., 2007, 17, 1349-1354
45. Bunnage, M. E.; Owen, D. R. TAFIa inhibitors in the treatment of thrombosis. Curr. Opin. Drug Discov. Dev., 2008, 11, 480-486
46. Wang, Y. X.; da, C., V; Vincelette, J.; Zhao, L.; Nagashima, M.; Kawai, K.; Yuan, S.; Emayan, K.; Islam, I.; Hosoya, J.; Sullivan, M. E.; Dole, W. P.; Morser, J.; Buckman, B. O.; Vergona, R. A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis. Thromb. Haemost., 2007, 97, 54-61. (Pubitemid 46242387)
47. Wang, Y. X.; Zhao, L.; Nagashima, M.; Vincelette, J.; Sukovich, D.; Li, W.; Subramanyam, B.; Yuan, S.; Emayan, K.; Islam, I.; Hrvatin, P.; Bryant, J.; Light, D. R.; Vergona, R.; Morser, J.; Buckman, B. O. A novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) - part I: pharmacological characterization. Thromb. Haemost., 2007, 97, 45-53.
48. Wang, X.; Smith, P. L.; Hsu, M. Y.; Ogletree, M. L.; Schumacher, W. A. Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor. J. Thromb. Haemost., 2006, 4, 403-410
49. Gils, A.; Ceresa, E.; Macovei, A. M.; Marx, P. F.; Peeters, M.; Compernolle, G.; Declerck, P. J. Modulation of TAFI function through different pathways - implications for the development of TAFI inhibitors. J. Thromb. Haemost., 2005, 3, 2745-2753
50. Schneider, M.; Nesheim, M. Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis. J. Thromb. Haemost., 2003, 1, 147-154
51. Walker, J. B.; Hughes, B.; James, I.; Haddock, P.; Kluft, C.; Bajzar, L. Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro. J. Biol. Chem., 2003, 278, 8913-8921 (Pubitemid 36800367)
52. Leurs, J.; Nerme, V.; Sim, Y.; Hendriks, D. Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism. J. Thromb. Haemost., 2004, 2, 416-423
53. Walker, J. B.; Bajzar, L. The intrinsic threshold of the fibriolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability. J. Biol. Chem., 2004, 279, 27896-27904 (Pubitemid 38900058)
54. Brouwers, G. J.; Vos, H. L.; Leebeek, F. W.; Bulk, S.; Schneider, M.; Boffa, M.; Koschinsky, M. L.; Van Tilburg, N. H.; Nesheim, M.; Bertina, R. M.; Gomez-Garcia, E. B. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood, 2001, 98, 1992-1993
55. Schneider, M.; Boffa, M.; Stewart, R. J.; Rahman, N. L.; Koschinsky, M. L.; Nesheim, M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J. Biol. Chem., 2002, 277, 1021-1030 (Pubitemid 34968847)
56. Henry, M.; Aubert, H.; Morange, P. E.; Nanni, I.; Alessi, M. C.; Tiret, L.; Juhan-Vague, I. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood, 2001, 97, 2053-2058 (Pubitemid 32239086)
57. Franco, R. F.; Fagundes, M. G.; Meijers, J. C. M.; Reitsma, P. H.; Lourenco, D.; Morelli, V.; Maffei, F. H.; Ferrari, I. C.; Piccinato, C. E.; Silva, W. A. j.; Zago, M. A. Identification of polymorphisms in the 5′-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica, 2001, 86, 510-517 (Pubitemid 33638980)
58. Koschinsky, M. L.; Boffa, M. B.; Nesheim, M. E.; Zinman, B.; Hanley, A. J.; Harris, S. B.; Cao, H.; Hegele, R. A. Association of a single nucleotide polymorphism in CPB2 encoding the thrombin-activable fibrinolysis inhibitor (TAF1) with blood pressure. Clin. Genet., 2001, 60, 345-349
59. Morange, P. E.; Juhan-Vague, I.; Scarabin, P. Y.; Alessi, M. C.; Luc, G.; Arveiler, D.; Ferrieres, J.; Amouyel, P.; Evans, A.; Ducimetiere, P. Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence. Thromb. Haemost., 2003, 89, 554-560 (Pubitemid 36329248)
60. Kremer Hovinga, J. A.; Franco, R. F.; Zago, M. A.; Ten, C. H.; Westendorp, R. G.; Reitsma, P. H. A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease. J. Thromb. Haemost., 2004, 2, 54-57 (Pubitemid 40185619)
61. de Bruijne, E. L.; Murad, S. D.; de Maat, M. P.; Tanck, M. W.; Haagsma, E. B.; van, H. B.; Rosendaal, F. R.; Janssen, H. L.; Leebeek, F. W. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis. Thromb. Haemost., 2007, 97, 181-185
62. Fernandez-Cadenas, I.; varez-Sabin, J.; Ribo, M.; Rubiera, M.; Mendioroz, M.; Molina, C. A.; Rosell, A.; Montaner, J. Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients. J. Thromb. Haemost., 2007, 5, 1862-1868
63. Masini, S.; Ticconi, C.; Gravina, P.; Tomassini, M.; Pietropolli, A.; Forte, V.; Federici, G.; Piccione, E.; Bernardini, S. Thrombin-activatable fibrinolysis inhibitor polymorphisms and recurrent pregnancy loss. Fertil. Steril., 2008, 90, 2107-2177.
64. Vanhoof, G.; Wauters, J.; Schatteman, K.; Hendriks, D.; Goossens, F.; Bossuyt, P.; Scharpé, S. The gene for human carboxypeptidase U (CPU)- a proposed novel regulator of plasminogen activation-maps to 13q14.11. Genomics, 1996, 38, 454-455 (Pubitemid 27030141)
65. Tsai, S. P.; Drayna, D. The gene encoding human plasma carboxypeptidase B (CPB2) resides on chromosome 13. Genomics, 1992, 14, 549-550
66. Boffa, M.; Reid, S. T.; Joo, E.; Nesheim, M.; Koschinsky, M. L. Characterization of the gene encoding human TAFI (Thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidas B). Biochem., 1999, 38, 6547-6558 (Pubitemid 129514953)
67. Garand, M.; Bastajian, N.; Nesheim, M. E.; Boffa, M. B.; Koschinsky, M. L. Molecular analysis of the human thrombin-activatable fibrinolysis inhibitor gene promoter. Br. J. Haematol., 2007, 138, 231-244 (Pubitemid 46976324)
68. Marx, P. F.; Wagenaar, G. T. M.; Reijerkerk, A.; Tiekstra, M. J.; Van Rossum, A. G.; Gebbink, M. F.; Meijers, J. C. Characterization of mouse thrombin-activatable fibrinolysis inhibitor. Thromb. Haemost., 2000, 83, 297-303.
69. Mosnier, L. O.; Buijtenhuijs, P.; Marx, P. F.; Meijers, J. C. M.; Bouma, B. N. Identification of Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in human platelets. Blood, 2003, 101, 4844-4846 (Pubitemid 36857744)
70. Bajzar, L.; Nesheim, M. E.; Tracy, P. B. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood, 1996, 88, 2093-2100 (Pubitemid 26307911)
71. Mosnier, L. O.; Von dem Borne, P. A.; Meijers, J. C.; Bouma, B. N. Plasma TAFI levels determine the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb. Haemost., 1998, 80, 829-835
72. Van Tilburg, N. H.; Rosendaal, F. R.; Bertina, R. M. Thrombin-activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood, 2000, 95, 2855-2859 (Pubitemid 30235895)
73. Strömqvist, M.; Schatteman, K.; Leurs, J.; Verkerk, R.; Andersson, J.; Johansson, T.; Scharpé, S.; Hendriks, D. Immunological assay for the determination of procarboxypeptidase U antigen levels in human plasma. Thromb. Haemost., 2001, 85, 12-17 (Pubitemid 32051336)
74. Frere, C.; Morange, P. E.; Saut, N.; Tregouet, D. A.; Grosley, M.; Beltran, J.; Juhan-Vague, I.; Alessi, M. C. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact. Thromb. Haemost., 2005, 94, 373-379
75. Boffa, M. B.; Hamill, J. D.; Maret, D.; Brown, D.; Scott, M. L.; Nesheim, M. E.; Koschinsky, M. L. Acute phase mediators modulate Thrombin-activable Fibrinolysis Inhibitor (TAFI) gene expression in HepG2 cells. J. Biol. Chem., 2003, 278, 9250-9257
76. Gils, A.; Alessi, M. C.; Brouwers, E.; Peeters, M.; Marx, P.; Leurs, J.; Bouma, B.; Hendriks, D.; Juhan-Vague, I.; Declerck, P. J. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 1122-1127
77. Willemse, J. L.; Matus, V.; Heylen, E.; Mezzano, D.; Hendriks, D. F. Influence of the Thr325Ile polymorphism on procarboxypeptidase U (thrombin-activable fibrinolysis inhibitor) activity-based assays. J. Thromb. Haemost., 2007, 5, 872-875
78. Willemse, J.; Leurs, J.; Verkerk, R.; Hendriks, D. Development of a fast kinetic method for the determination of carboxypeptidase U (TAFIa) using C-terminal arginine containing peptides as substrate. Anal. Biochem., 2005, 340, 106-112 (Pubitemid 40404106)
79. Willemse, J. L.; Leurs, J. R.; Hendriks, D. F. Fast kinetic assay for the determination of procarboxypeptidase U (TAFI) in human plasma. J. Thromb. Haemost., 2005, 3, 2353-2355
80. Kim, P. Y.; Foley, J.; Hsu, G.; Kim, P. Y.; Nesheim, M. E. An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma. Anal. Biochem., 2008, 372, 32-40.
81. Ceresa, E.; Brouwers, E.; Peeters, M.; Jern, C.; Declerck, P. J.; Gils, A. Development of ELISAs measuring the extent of TAFI activation. Arterioscler. Thromb. Vasc. Biol., 2006, 26, 423-428 (Pubitemid 43732210)
82. Hillmayer, K.; Macovei, A.; Pauwels, D.; Compernolle, G.; Declerck, P. J.; Gils, A. Characterization of rat thrombin-activatable fibrinolysis inhibitor (TAFI) - a comparative study assessing the biological equivalence of rat, murine and human TAFI. J. Thromb. Haemost., 2006, 4, 2470-2477 (Pubitemid 44575443)
83. Hillmayer, K.; Brouwers, E.; Leon-Tamariz, F.; Meijers, J. C.; Marx, P. F.; Declerck, P. J.; Gils, A. Development of sandwich-type ELISAs for the quantification of rat and murine thrombin activatable fibrinolysis inhibitor in plasma. J. Thromb. Haemost., 2008, 6, 132-138
84. Te Velde, E. A.; Wagenaar, G. T.; Reijerkerk, A.; Roose-Girma, M.; Borel, R., I; Voest, E. E.; Bouma, B. N.; Gebbink, M. F.; Meijers, J. C. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J. Thromb. Haemost., 2003, 1, 2087-2096
85. Guimaraes, A. H.; Barrett-Bergshoeff, M. M.; Criscuoli, M.; Evangelista, S.; Rijken, D. C. Fibrinolytic efficacy of Amediplase, Tenecteplase and scu-PA in different external plasma clot lysis models: sensitivity to the inhibitory action of thrombin activatable fibrinolysis inhibitor (TAFI). Thromb. Haemost., 2006, 96, 325-330
86. Guimaraes, A. H.; Bertina, R. M.; Rijken, D. C. A new functional assay of thrombin activatable fibrinolysis inhibitor. J. Thromb. Haemost., 2005, 3, 1284-1292 (Pubitemid 41725254)
87. Rijken, D. C.; Hoegee-de, N. E.; Jie, A. F.; Atsma, D. E.; Schalij, M. J.; Nieuwenhuizen, W. Development of a new test for the global fibrinolytic capacity in whole blood. J. Thromb. Haemost., 2008, 6, 151-157
88. Willemse, J. L.; Polla, M.; Olsson, T.; Hendriks, D. F. Comparative substrate specificity study of carboxypeptidase U (TAFIa) and carboxypeptidase N: development of highly selective CPU substrates as useful tools for assay development. Clin. Chim. Acta, 2008, 387, 158-160
89. Hillmayer, K.; Ceresa, E.; Vancraenenbroeck, R.; Declerck, P. J.; Gils, A. Conformational (in)stability of rat TAFIa versus human TAFIa. J. Thromb. Haemost., 2008, 6, 1426-1428
90. Schatteman, K. A.; Goossens, F. J.; Scharpe, S. S.; Hendriks, D. F. Activation of plasma procarboxypeptidase U in different mammalian species points to a conserved pathway of inhibition of fibrinolysis. Thromb. Haemost., 1999, 82, 1718-1721
91. Schroeder, V.; Chatterjee, T.; Mehta, H.; Windecker, S.; Pham, T.; Devantay, N.; Meier, B.; Kohler, H. P. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb. Haemost., 2002, 88, 1020-1025
92. Schroeder, V.; Wilmer, M.; Buehler, B.; Kohler, H. P. TAFI activity in coronary artery disease: a contribution to the current discussion on TAFI assays. Thromb. Haemost., 2006, 96, 236-237
93. Kitagawa, N.; Yano, Y.; Gabazza, E. C.; Bruno, N. E.; Araki, R.; Matsumoto, K.; Katsuki, A.; Hori, Y.; Nakatani, K.; Taguchi, O.; Sumida, Y.; Suzuki, K.; Adachi, Y. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients. Diabetes Res. Clin. Pract., 2006, 73, 150-157 (Pubitemid 43928156)
94. Yano, Y.; Kitagawa, N.; Gabazza, E. C.; Morioka, K.; Urakawa, H.; Tanaka, T.; Katsuki, A.; Araki-Sasaki, R.; Hori, Y.; Nakatani, K.; Taguchi, O.; Sumida, Y.; Adachi, Y. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normatensive type 2 diabetic patients with microalbuminuria. J. Clin. Endocrinol. Metabolism, 2003, 88, 736-741 (Pubitemid 36207816)
95. Yano, Y.; Gabazza, E. C.; Hori, Y.; Kitagawa, N.; Katsuki, A.; raki-Sasaki, R.; Sumida, Y.; Adachi, Y. Association between plasma thrombin-activatable fibrinolysis inhibitor levels and acti vated protein C in normotensive type 2 diabetic patients. Diabetes Care, 2002, 25, 1245-1246
96. Hori, Y.; Gabazza, E. C.; Yano, Y.; Katsuki, A.; Suzuki, K.; Adachi, Y.; Sumida, Y. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J. Clin. Endocrinol. Metab, 2002, 87, 660-665 (Pubitemid 34158234)
97. Malyszko, J.; Tymcio, J. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension. Pol. Arch. Med. Wewn., 2008, 118, 36-41. (Pubitemid 351316526)
98. Malyszko, J.; Malyszko, J. S.; Hryszko, T.; Mysliwiec, M. Thrombin activatable fibrinolysis inhibitor in hypertensive kidney transplant recipients. Transplant. Proc., 2006, 38, 105-107 (Pubitemid 43303610)
99. Guven, G. S.; Kilicaslan, A.; Oz, S. G.; Haznedaroglu, I. C.; Kirazli, S.; Aslan, D.; Sozen, T. Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity. Clin. Appl. Thromb. Hemost., 2006, 12, 364-368 (Pubitemid 44400850)
100. Rooth, E.; Wallen, H.; Antovic, A.; von, A. M.; Kaponides, G.; Wahlgren, N.; Blomback, M.; Antovic, J. Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke. Blood Coagul. Fibrinolysis, 2007, 18, 365-370 (Pubitemid 46699415)
101. Ladenvall, C.; Gils, A.; Jood, K.; Blomstrand, C.; Declerck, P. J.; Jern, C. Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation. Arterioscler. Thromb. Vasc. Biol., 2007, 27, 955-962 (Pubitemid 46606731)
102. Leebeek, F. W.; Goor, M. P.; Guimaraes, A. H.; Brouwers, G. J.; Maat, M. P.; Dippel, D. W.; Rijken, D. C. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J. Thromb. Haemost., 2005, 3, 2211-2218
103. Monasterio, J.; Bermudez, P.; Quiroga, D.; Francisco, E.; Meneses, B.; Montaner, J. Plasma thrombin-activatable fibrinolytic inhibitor (TAFI) among healthy subjects and patients with vascular diseases: a validation study. Pathophysiol. Haemost. Thromb., 2003, 33, 382-386 (Pubitemid 40278712)
104. Ribo, M.; Montaner, J.; Molina, C. A.; Arenillas, J. F.; Santamarina, E.; Quintana, M.; varez-Sabin, J. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke, 2004, 35, 2123-2127
105. Santamaria, A.; Oliver, A.; Borrell, M.; Mateo, J.; Belvis, R.; Marti-Fabregas, J.; Ortin, R.; Tirado, I.; Souto, J. C.; Fontcuberta, J. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke, 2003, 34, 2387-2391 (Pubitemid 37229070)
106. Montaner, J.; Ribo, M.; Monasterio, J.; Molina, C. A.; Alvarez-Sabin, J. Thrombin-Activable Fibrinolysis Inhibitor levels in the acute phase of ischemic stroke. Stroke, 2003, 1038-1040 (Pubitemid 36402986)
107. Emonts, M.; de Bruijne, E. L.; Guimaraes, A. H.; Declerck, P. J.; Leebeek, F. W.; de Maat, M. P.; Rijken, D. C.; Hazelzet, J. A.; Gils, A. Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children. J. Thromb. Haemost., 2008, 6, 268-276 (Pubitemid 351144609)
108. Zeerleder, S.; Schroeder, V.; Hack, C. E.; Kohler, H. P.; Wuillemin, W. A. TAFI and PAI-1 levels in human sepsis. Thromb. Res., 2006, 118, 205-212
109. Watanabe, R.; Wada, H.; Watanabe, Y.; Sakakura, M.; Nakasaki, T.; Mori, Y.; Nishikawa, M.; Gabazza, E. C.; Nobori, T.; Shiku, H. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb. Res., 2001, 104, 1-6. (Pubitemid 32918249)
110. Gresele, P.; Binetti, B. M.; Branca, G.; Clerici, C.; Asciutti, S.; Morelli, A.; Semeraro, N.; Colucci, M. TAFI deficiency in liver cirrhosis: relation with plasma fibrinolysis and survival. Thromb. Res., 2008, 121, 763-768
111. Bruno, N. E.; Yano, Y.; Takei, Y.; Qin, L.; Suzuki, T.; Morser, J.; essandro-Gabazza, C. N.; Mizoguchi, A.; Suzuki, K.; Taguchi, O.; Gabazza, E. C.; Sumida, Y. Immune complex-mediated glomerulonephritis is ameliorated by thrombin-activatable fibrinolysis inhibitor deficiency. Thromb. Haemost., 2008, 100, 90-100.
112. Rigla, M.; Wagner, A. M.; Borrell, M.; Mateo, J.; Foncuberta, J.; de, L. A.; Ordonez-Llanos, J.; Perez, A. Postprandial thrombin activatable fibrinolysis inhibitor and markers of endothelial dysfunction in type 2 diabetic patients. Metabolism, 2006, 55, 1437-1442 (Pubitemid 44537340)
113. Ribo, M.; Montaner, J.; Molina, C. A.; Arenillas, J. F.; Santamarina, E.; varez-Sabin, J. Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thromb. Haemost., 2004, 91, 1146-1151 (Pubitemid 38821271)
114. Nagashima, M.; Yin, Z. F.; Zhao, L.; White, K.; Zhu, Y.; Lasky, N.; Halks-Miller, M.; Broze, G. J., Jr.; Fay, W. P.; Morser, J. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J. Clin. Invest, 2002, 109, 101-110 (Pubitemid 34052546)
115. Asai, S.; Sato, T.; Tada, T.; Miyamoto, T.; Kimbara, N.; Motoyama, N.; Okada, H.; Okada, N. Absence of procarboxypeptidase R induces complement-mediated lethal inflammation in lipopolysaccharide-primed mice. J. Immunol., 2004, 173, 4669-4674 (Pubitemid 39280701)
116. Wang, X.; Smith, P. L.; Hsu, M. Y.; Tamasi, J. A.; Bird, E.; Schumacher, W. A. Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis. J. Thromb. Thrombolysis., 2007, 23, 41-49
117. Mao, S. S.; Holahan, M. A.; Bailey, C.; Wu, G.; Colussi, D.; Carroll, S. S.; Cook, J. J. Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice. Blood Coagul. Fibrinolysis, 2005, 16, 407-415
118. Swaisgood, C. M.; Schmitt, D.; Eaton, D. L.; Plow, E. F. In vivo regulation of plasminogen function by plasma carboxypeptidase B. J. Clin. Invest., 2002, 110, 1275-1282
119. Renckens, R.; Roelofs, J. J.; ter Horst, S. A.; van, '., V; Havik, S. R.; Florquin, S.; Wagenaar, G. T.; Meijers, J. C.; van der, P. T. Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice. J. Immunol., 2005, 175, 6764-6771
120. Pahlman, L. I.; Marx, P. F.; Morgelin, M.; Lukomski, S.; Meijers, J. C.; Herwald, H. Thrombin-activatable fibrinolysis inhibitor binds to Streptococcus pyogenes by interacting with collagen-like proteins A and B. J. Biol. Chem., 2007, 282, 24873-24881 (Pubitemid 47347522)
121. Bengtson, S.; Sadén, C.; Mörgelin, M.; Marx, P. F.; Olin, A.; Leeb- Lundberg, L.; Meijers, J. C. M.; Herwald, H. Activation of TAFI on the Surface of Streptococcus pyogenes Evokes Inflammatory Reactions by Modulating the Kallikrein/Kinin System. J. Innate Immun., 2009, 1, 18-28.
122. Guimaraes, A. H.; Laurens, N.; Weijers, E. M.; Koolwijk, P.; van, H., V; Rijken, D. C. TAFI and pancreatic carboxypeptidase B modulate in vitro capillary tube formation by human microvascular endothelial cells. Arterioscler. Thromb. Vasc. Biol., 2007, 27, 2157-2162